Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Interaction of translationally controlled tumor protein with Apaf-1 is involved in the development of chemoresistance in HeLa cells

Authors: Jaehoon Jung, Hyo Young Kim, Jeehye Maeng, Moonhee Kim, Dong Hae Shin, Kyunglim Lee

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Translationally controlled tumor protein (TCTP), alternatively called fortilin, is believed to be involved in the development of the chemoresistance of tumor cells against anticancer drugs such as etoposide, taxol, and oxaliplatin, the underlying mechanisms of which still remain elusive.

Methods

Cell death analysis of TCTP-overexpressing HeLa cells was performed following etoposide treatment to assess the mitochondria-dependent apoptosis. Apoptotic pathway was analyzed through measuring the cleavage of epidermal growth factor receptor (EGFR) and phospholipase C-γ (PLC-γ), caspase activation, mitochondrial membrane perturbation, and cytochrome c release by flow cytometry and western blotting. To clarify the role of TCTP in the inhibition of apoptosome, in vitro apoptosome reconstitution and immunoprecipitation was used. Pull-down assay and silver staining using the variants of Apaf-1 protein was applied to identify the domain that is responsible for its interaction with TCTP.

Results

In the present study, we confirmed that adenoviral overexpression of TCTP protects HeLa cells from cell death induced by cytotoxic drugs such as taxol and etoposide. TCTP antagonized the mitochondria-dependent apoptotic pathway following etoposide treatment, including mitochondrial membrane damage and resultant cytochrome c release, activation of caspase-9, and -3, and eventually, the cleavage of EGFR and PLC-γ. More importantly, TCTP interacts with the caspase recruitment domain (CARD) of Apaf-1 and is incorporated into the heptameric Apaf-1 complex, and that C-terminal cleaved TCTP specifically associates with Apaf-1 of apoptosome in apoptosome-forming condition thereby inhibiting the amplification of caspase cascade.

Conclusions

TCTP protects the cancer cells from etoposide-induced cell death by inhibiting the mitochondria-mediated apoptotic pathway. Interaction of TCTP with Apaf-1 in apoptosome is involved in the molecular mechanism of TCTP-induced chemoresistance. These findings suggest that TCTP may serve as a therapeutic target for chemoresistance in cancer treatment.
Appendix
Available only for authorised users
Literature
1.
Bommer UA, Thiele BJ: The translationally controlled tumour protein (TCTP). Int J Biochem Cell Biol. 2004, 36 (3): 379-385. 10.1016/S1357-2725(03)00213-9.CrossRefPubMed
2.
Kim M, Min HJ, Won HY, Park H, Lee JC, Park HW, Chung J, Hwang ES, Lee K: Dimerization of translationally controlled tumor protein is essential for its cytokine-like activity. PLoS One. 2009, 4 (7): e6464-10.1371/journal.pone.0006464.CrossRefPubMedPubMedCentral
3.
Li F, Zhang D, Fujise K: Characterization of fortilin, a novel antiapoptotic protein. J Biol Chem. 2001, 276 (50): 47542-47549. 10.1074/jbc.M108954200.CrossRefPubMed
4.
Telerman A, Amson R: The molecular programme of tumour reversion: the steps beyond malignant transformation. Nat Rev Cancer. 2009, 9 (3): 206-216. 10.1038/nrc2589.CrossRefPubMed
5.
Tuynder M, Susini L, Prieur S, Besse S, Fiucci G, Amson R, Telerman A: Biological models and genes of tumor reversion: cellular reprogramming through tpt1/TCTP and SIAH-1. Proc Natl Acad Sci USA. 2002, 99 (23): 14976-14981. 10.1073/pnas.222470799.CrossRefPubMedPubMedCentral
6.
Liu H, Peng HW, Cheng YS, Yuan HS, Yang-Yen HF: Stabilization and enhancement of the antiapoptotic activity of mcl-1 by TCTP. Mol Cell Biol. 2005, 25 (8): 3117-3126. 10.1128/MCB.25.8.3117-3126.2005.CrossRefPubMedPubMedCentral
7.
Susini L, Besse S, Duflaut D, Lespagnol A, Beekman C, Fiucci G, Atkinson AR, Busso D, Poussin P, Marine JC, Martinou JC, Cavarelli J, Moras D, Amson R, Telerman A: TCTP protects from apoptotic cell death by antagonizing bax function. Cell death Differ. 2008, 15 (8): 1211-1220. 10.1038/cdd.2008.18.CrossRefPubMed
8.
Yang Y, Yang F, Xiong Z, Yan Y, Wang X, Nishino M, Mirkovic D, Nguyen J, Wang H, Yang XF: An N-terminal region of translationally controlled tumor protein is required for its antiapoptotic activity. Oncogene. 2005, 24 (30): 4778-4788. 10.1038/sj.onc.1208666.CrossRefPubMedPubMedCentral
9.
Kim M, Jung Y, Lee K, Kim C: Identification of the calcium binding sites in translationally controlled tumor protein. Arch Pharm Res. 2000, 23 (6): 633-636. 10.1007/BF02975253.CrossRefPubMed
10.
Graidist P, Yazawa M, Tonganunt M, Nakatomi A, Lin CC, Chang JY, Phongdara A, Fujise K: Fortilin binds Ca2+ and blocks Ca2+ -dependent apoptosis in vivo. Biochem J. 2007, 408 (2): 181-191. 10.1042/BJ20070679.CrossRefPubMedPubMedCentral
11.
Amson R, Pece S, Lespagnol A, Vyas R, Mazzarol G, Tosoni D, Colaluca I, Viale G, Rodrigues-Ferreira S, Wynendaele J, Chaloin O, Hoebeke J, Marine JC, Di Fiore PP, Telerman A: Reciprocal repression between P53 and TCTP. Nat Med. 2012, 18 (1): 91-99.CrossRef
12.
Rho SB, Lee JH, Park MS, Byun HJ, Kang S, Seo SS, Kim JY, Park SY: Anti-apoptotic protein TCTP controls the stability of the tumor suppressor p53. FEBS Lett. 2011, 585 (1): 29-35. 10.1016/j.febslet.2010.11.014.CrossRefPubMed
13.
Jung J, Kim HY, Kim M, Sohn K, Lee K: Translationally controlled tumor protein induces human breast epithelial cell transformation through the activation of Src. Oncogene. 2011, 30 (19): 2264-2274. 10.1038/onc.2010.604.CrossRefPubMed
14.
Bommer UA, Heng C, Perrin A, Dash P, Lobov S, Elia A, Clemens MJ: Roles of the translationally controlled tumour protein (TCTP) and the double-stranded RNA-dependent protein kinase, PKR, in cellular stress responses. Oncogene. 2010, 29 (5): 763-773. 10.1038/onc.2009.380.CrossRefPubMed
15.
Graidist P, Phongdara A, Fujise K: Antiapoptotic protein partners fortilin and MCL1 independently protect cells from 5-fluorouracil-induced cytotoxicity. J Biol Chem. 2004, 279 (39): 40868-40875. 10.1074/jbc.M401454200.CrossRefPubMed
16.
Sinha P, Kohl S, Fischer J, Hutter G, Kern M, Kottgen E, Dietel M, Lage H, Schnolzer M, Schadendorf D: Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis. 2000, 21 (14): 3048-3057. 10.1002/1522-2683(20000801)21:14<3048::AID-ELPS3048>3.0.CO;2-W.CrossRefPubMed
17.
Bull VH, Fargestad EM, Strozynski M, Thiede B: Temporal proteome profiling of taxol-induced mitotic arrest and apoptosis. Electrophoresis. 2010, 31 (11): 1873-1885. 10.1002/elps.200900780.CrossRefPubMed
18.
Yao Y, Jia XY, Tian HY, Jiang YX, Xu GJ, Qian QJ, Zhao FK: Comparative proteomic analysis of colon cancer cells in response to oxaliplatin treatment. Biochimica et biophysica acta. 2009, 1794 (10): 1433-1440. 10.1016/j.bbapap.2009.06.005.CrossRefPubMed
19.
Fadeel B, Ottosson A, Pervaiz S: Big wheel keeps on turning: apoptosome regulation and its role in chemoresistance. Cell Death Differ. 2008, 15 (3): 443-452. 10.1038/sj.cdd.4402265.CrossRefPubMed
20.
Kaufmann SH, Vaux DL: Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene. 2003, 22 (47): 7414-7430. 10.1038/sj.onc.1206945.CrossRefPubMed
21.
Campioni M, Santini D, Tonini G, Murace R, Dragonetti E, Spugnini EP, Baldi A: Role of Apaf-1, a key regulator of apoptosis, in melanoma progression and chemoresistance. Exp Dermatol. 2005, 14 (11): 811-818. 10.1111/j.1600-0625.2005.00360.x.CrossRefPubMed
22.
Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordón-Cardó C, Lowe SW: Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature. 2001, 409 (6817): 207-211. 10.1038/35051606.CrossRefPubMed
23.
Anichini A, Mortarini R, Sensi M, Zanon M: APAF-1 signaling in human melanoma. Cancer Lett. 2006, 238 (2): 168-179. 10.1016/j.canlet.2005.06.034.CrossRefPubMed
24.
Sun Y, Orrenius S, Pervaiz S, Fadeel B: Plasma membrane sequestration of apoptotic protease-activating factor-1 in human B-lymphoma cells: a novel mechanism of chemoresistance. Blood. 2005, 105 (10): 4070-4077. 10.1182/blood-2004-10-4075.CrossRefPubMed
25.
Kamarajan P, Sun NK, Sun CL, Chao CC: Apaf-1 overexpression partially overcomes apoptotic resistance in a cisplatin-selected HeLa cell line. FEBS Lett. 2001, 505 (2): 206-212. 10.1016/S0014-5793(01)02817-4.CrossRefPubMed
26.
Hu Y, Benedict MA, Wu D, Inohara N, Nunez G: Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci USA. 1998, 95 (8): 4386-4391. 10.1073/pnas.95.8.4386.CrossRefPubMedPubMedCentral
27.
Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, Tailor P, Morimoto RI, Cohen GM, Green DR: Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol. 2000, 2 (8): 469-475. 10.1038/35019501.CrossRefPubMed
28.
Cho DH, Hong YM, Lee HJ, Woo HN, Pyo JO, Mak TW, Jung YK: Induced inhibition of ischemic/hypoxic injury by APIP, a novel Apaf-1-interacting protein. J Biol Chem. 2004, 279 (38): 39942-39950. 10.1074/jbc.M405747200.CrossRefPubMed
29.
Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES: Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell. 1998, 1 (7): 949-957. 10.1016/S1097-2765(00)80095-7.CrossRefPubMed
30.
Benjamin CW, Hiebsch RR, Jones DA: Caspase activation in MCF7 cells responding to etoposide treatment. Mol Pharmacol. 1998, 53 (3): 446-450.PubMed
31.
Park SJ, Wu CH, Gordon JD, Zhong X, Emami A, Safa AR: Taxol induces caspase-10-dependent apoptosis. J Biol Chem. 2004, 279 (49): 51057-51067. 10.1074/jbc.M406543200.CrossRefPubMed
32.
Bae SS, Perry DK, Oh YS, Choi JH, Galadari SH, Ghayur T, Ryu SH, Hannun YA, Suh PG: Proteolytic cleavage of phospholipase C-gamma1 during apoptosis in Molt-4 cells. FASEB J. 2000, 14 (9): 1083-1092.PubMed
33.
He YY, Huang JL, Chignell CF: Cleavage of epidermal growth factor receptor by caspase during apoptosis is independent of its internalization. Oncogene. 2006, 25 (10): 1521-1531. 10.1038/sj.onc.1209184.CrossRefPubMed
34.
Wang X: The expanding role of mitochondria in apoptosis. Genes Dev. 2001, 15 (22): 2922-2933.PubMed
35.
Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997, 91 (4): 479-489. 10.1016/S0092-8674(00)80434-1.CrossRefPubMed
36.
Liu X, Kim CN, Yang J, Jemmerson R, Wang X: Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 1996, 86 (1): 147-157. 10.1016/S0092-8674(00)80085-9.CrossRefPubMed
37.
Li J, Yuan J: Caspases in apoptosis and beyond. Oncogene. 2008, 27 (48): 6194-6206. 10.1038/onc.2008.297.CrossRefPubMed
38.
Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG: Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 1993, 53 (17): 3976-3985.PubMed
39.
Rudolf K, Cervinka M, Rudolf E: Cytotoxicity and mitochondrial apoptosis induced by etoposide in melanoma cells. Cancer Invest. 2009, 27 (7): 704-717. 10.1080/07357900802653480.CrossRefPubMed
40.
Jung J, Kim M, Kim MJ, Kim J, Moon J, Lim JS, Lee K: Translationally controlled tumor protein interacts with the third cytoplasmic domain of Na, K-ATPase alpha subunit and inhibits the pump activity in HeLa cells. J Biol Chem. 2004, 279 (48): 49868-49875. 10.1074/jbc.M400895200.CrossRefPubMed
41.
Jaffrezou JP, Chen G, Duran GE, Kuhl JS, Sikic BI: Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis. J Natl Cancer Inst. 1994, 86 (15): 1152-1158. 10.1093/jnci/86.15.1152.CrossRefPubMed
42.
Kubota N, Nishio K, Takeda Y, Ohmori T, Funayama Y, Ogasawara H, Ohira T, Kunikane H, Terashima Y, Saijo N: Characterization of an etoposide-resistant human ovarian cancer cell line. Cancer Chemother Pharmacol. 1994, 34 (3): 183-190. 10.1007/BF00685075.CrossRefPubMed
43.
Long BH, Wang L, Lorico A, Wang RC, Brattain MG, Casazza AM: Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res. 1991, 51 (19): 5275-5283.PubMed
44.
Minato K, Kanzawa F, Nishio K, Nakagawa K, Fujiwara Y, Saijo N: Characterization of an etoposide-resistant human small-cell lung cancer cell line. Cancer Chemother Pharmacol. 1990, 26 (5): 313-317. 10.1007/BF02897284.CrossRefPubMed
45.
Moitra K, Im K, Limpert K, Borsa A, Sawitzke J, Robey R, Yuhki N, Savan R, da Huang W, Lempicki RA, Bates S, Dean M: Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One. 2012, 7 (9): e45268-10.1371/journal.pone.0045268.CrossRefPubMedPubMedCentral
46.
Liu JR, Opipari AW, Tan L, Jiang Y, Zhang Y, Tang H, Nunez G: Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res. 2002, 62 (3): 924-931.PubMed
47.
Saleh A, Srinivasula SM, Balkir L, Robbins PD, Alnemri ES: Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat Cell Biol. 2000, 2 (8): 476-483. 10.1038/35019510.CrossRefPubMed
48.
Hietanen S, Lain S, Krausz E, Blattner C, Lane DP: Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci USA. 2000, 97 (15): 8501-8506. 10.1073/pnas.97.15.8501.CrossRefPubMedPubMedCentral
49.
Massip A, Arcondeguy T, Touriol C, Basset C, Prats H, Lacazette E: E2F1 activates p53 transcription through its distal site and participates in apoptosis induction in HPV-positive cells. FEBS Lett. 2013, 587 (19): 3188-3194. 10.1016/j.febslet.2013.08.009.CrossRefPubMed
50.
Zou H, Li Y, Liu X, Wang X: An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem. 1999, 274 (17): 11549-11556. 10.1074/jbc.274.17.11549.CrossRefPubMed
51.
Sirois I, Raymond MA, Brassard N, Cailhier JF, Fedjaev M, Hamelin K, Londono I, Bendayan M, Pshezhetsky AV, Hebert MJ: Caspase-3-dependent export of TCTP: a novel pathway for antiapoptotic intercellular communication. Cell Death Differ. 2011, 18 (3): 549-562. 10.1038/cdd.2010.126.CrossRefPubMed
52.
Tuynder M, Fiucci G, Prieur S, Lespagnol A, Geant A, Beaucourt S, Duflaut D, Besse S, Susini L, Cavarelli J, Moras D, Amson R, Telerman A: Translationally controlled tumor protein is a target of tumor reversion. Proc Natl Acad Sci USA. 2004, 101 (43): 15364-15369. 10.1073/pnas.0406776101.CrossRefPubMedPubMedCentral
53.
Berger TG, Dieckmann D, Efferth T, Schultz ES, Funk JO, Baur A, Schuler G: Artesunate in the treatment of metastatic uveal melanoma–first experiences. Oncol Rep. 2005, 14 (6): 1599-1603.PubMed
54.
Zhang ZY, Yu SQ, Miao LY, Huang XY, Zhang XP, Zhu YP, Xia XH, Li DQ: Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled trial. Zhong Xi Yi Jie He Xue Bao. 2008, 6 (2): 134-138. 10.3736/jcim20080206.CrossRefPubMed
Metadata
Title
Interaction of translationally controlled tumor protein with Apaf-1 is involved in the development of chemoresistance in HeLa cells
Authors
Jaehoon Jung
Hyo Young Kim
Jeehye Maeng
Moonhee Kim
Dong Hae Shin
Kyunglim Lee
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-165

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Enhanced down-regulation of ALCAM/CD166 in African-American Breast Cancer

Research article

COX-2 overexpression in resected pancreatic head adenocarcinomas correlates with favourable prognosis

Research article

Therapeutic effects of lentivirus-mediated shRNA targeting of cyclin D1 in human gastric cancer

Research article

CA15-3 is a useful serum tumor marker for diagnostic integration of hybrid positron emission tomography with integrated computed tomography during follow-up of breast cancer patients

Research article

ALDH1A1 expression correlates with clinicopathologic features and poor prognosis of breast cancer patients: a systematic review and meta-analysis

Research article

Inhibition of autophagy enhances the cytotoxic effect of PA-MSHA in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits